Teicoplanin


Generic Medicine Info
Contraindications
Hypersensitivity.
Special Precautions
Patient with history of red-man syndrome. Renal impairment. Elderly. Pregnancy and lactation. Patient Counselling This medicine may cause dizziness and headache, if affected, do not drive or operate machinery. Monitoring Parameters Monitor trough concentration at steady state after loading dose, and at least once a week during maintenance treatment. Perform culture and susceptibility tests before treatment initiation. Monitor CBC, liver and kidney function test.
Adverse Reactions
Significant: Thrombocytopenia, ototoxicity (deafness, tinnitus), renal failure, superinfection, red man syndrome manifested as pruritus, urticaria, erythema, angioneurotic oedema, tachycardia, hypotension, dyspnea. Blood and lymphatic system disorders: Leucopenia, eosinophilia, agranulocytosis, neutropenia. Gastrointestinal disorders: Diarrhoea, nausea, vomiting. General disorders and administration site conditions: Pain, pyrexia, injection site abscess. Infections and infestations: Abscess, superinfection. Investigations: Transaminases increased, blood alkaline phosphatase increased, blood creatinine increased. Nervous system disorders: Dizziness, headache, seizures. Renal and urinary disorders: Blood creatinine increased. Respiratory, thoracic and mediastinal disorders: Bronchospasm. Skin and subcutaneous tissue disorders: Rash, erythema, pruritus, dermatitis exfoliative. Vascular disorders: Phlebitis, thrombophlebitis.
Potentially Fatal: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), hypersensitivity reactions (e.g. anaphylactic shock).
Drug Interactions
Increased nephrotoxic effect with aminoglycosides, ciclosporin, cisplatin. Increased ototoxic effects with furosemide, ethacrynic acid.
CIMS Class
Other Antibiotics
ATC Classification
J01XA02 - teicoplanin ; Belongs to the class of glycopeptide antibacterials. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on teicoplanin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in